Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05305079 · ClinicalTrials.gov registry record
NA-AION Risk Factors: New Perspectives
A clinical trial, sponsored by Rigshospitalet, Denmark.
- Completed
- Registry status
- 179
- Enrollment target
NCT05305079: Completed study, sponsored by Rigshospitalet, Denmark.
NCT05305079 is a clinical trial that has completed, run by Rigshospitalet, Denmark. The registered enrollment target is 179 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05305079 has completed, sponsored by Rigshospitalet, Denmark.
- COMPLETED
- Registry status
- 179 participants
- Enrollment target
Study Summary
The purpose of the study is to use new diagnostic methods (OCT and OCT-A) to shed light on risk factors for the development of NA-AION. The risk factors we are focusing on are comorbidities along with anatomical and vascular characteristics of the optic nerve.
Primary Outcome
Presence of ODD. Diameter of the scleral canal, disc area and rim on each quadrant of the optic disc, thickness of the peripapillary choroid, presence of peripapillary hyperreflective ovoid mass-like structures, and prelaminar hyperreflective lines.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2021-08-01 |
| Est. Completion | 2024-08-31 |
What the finished NCT05305079 record still lists
NCT05305079 is an observational study that tracks outcomes without assigning an intervention. The registered 179 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05305079 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05305079 about?
NCT05305079 is a clinical study titled "NA-AION Risk Factors: New Perspectives". The purpose of the study is to use new diagnostic methods (OCT and OCT-A) to shed light on risk factors for the development of NA-AION. The risk factors we are focusing on are comorbidities along with anatomical and vascular characteristics of the optic nerve.
What is the current status of trial NCT05305079?
This trial is currently completed. The enrollment target is 179 participants. The study started on 2021-08-01. Estimated completion is 2024-08-31.
Who is sponsoring clinical trial NCT05305079?
This trial is sponsored by Rigshospitalet, Denmark, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06581198 · 179 participants · Phase 2
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
- NCT07356323 · 179 participants · NA
A Prospective, Single-arm, Trial to Determine Contamination Rates When Using an Antibacterial Incise Drape During Orthopedic Surgery
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI